Uma t�cnica desenvolvida por uma equipe de Lausanne e de Chicago emprega uma terapia gen�tica para deter a morte das c�lulas dopaminergicas. Trata-se da utiliza��o de um v�rus inofensivo que transporta um fator de crescimento de nervos. Este fator de crescimento, uma vez instalado no c�rebro, retarda e impede a deteriora��o das c�lulas. Os testes feitos em ratos e depois em macacos mostraram que n�o somente a tecnica retarda a morte das c�lulas como restabelece a capacidade das mesmas de produzir dopamina. Segundo os pesquisadores essa t�cnica seria atualmente a mais promissora no tratamento da DP e tamb�m de outras patologias. Os testes cl�nicos em seres humanos devem ocorrer dentro de cinco anos.
FONTE:
-----Mensagem Original-----
De: M.Schild
Enviado: segunda-feira, 28 de outubro de 2002 10:02
Para: Parkliste
Assunto: recherche
Une technique mis au point par une equipe de Lausanne et de Chicago mettent
au point un thrapie genique pour freine la mort des cellules dopaminergiques.
Il s'agit d'utiliser un virus inoffensif qui porte un facteur de croissance
de nerfs. Ce facteur de croissance, un fois en place dans le cerveau, ralenti
et stoppe la degenerescence des cellules. Les essais effectues sur les rats
puis les singes monent que non seulement cett techniqu alenti la mort mais d
cellules ont l'air de se regenerer la production de dopamine dans les celluls
atteintes. D'apres les chercheurs, ctte technique serait actuellement la plus
prometteuse dans le traitement d la MP et pourrait servir a d'autres
pathologies. Ls essais cliniques devraint commencer prochainement.
Gene Therapy Very Promising, Very Preliminary for Parkinson's
Technique May Be Tested in Humans Within Five Years
By Neil Osterweil
WebMD Medical News
Reviewed by Dr. Jacqueline Brooks
Oct. 26, 2000 -- Gene therapy for the prevention and treatment of
Parkinson's disease has taken another step closer to reality, say U.S.
and Swiss researchers in the Oct. 27 issue of the journal Science.
More than one million Americans have been diagnosed with Parkinson's,
which causes symptoms such as trembling, rigid muscles, and loss of the
ability to control voluntary movements. The disease is caused by the
progressive death of nerve cells in the brain that produce a chemical
called dopamine, which helps the central nervous system to control
normal movements.
But as researchers from Rush-Presbyterian-St. Luke's Medical Center in
Chicago and Lausanne University Medical School in Switzerland report, a
new form of gene therapy can both stop the destruction of
dopamine-producing nerve cells and improve control of body movement in
monkeys with a syndrome similar to Parkinson's disease. The researchers
used a virus engineered to be harmless and carry nerve growth factor,
the gene that sparks nerve growth, into the brain.
"I think it's the most promising potential new therapy we have in the
pipeline," says Parkinson's disease researcher Martha C. Bohn, MD,
professor of pediatrics, molecular biology, and biological chemistry at
Northwestern University in Chicago, tells WebMD.
In rats, and now in monkeys, this form of gene therapy "is very
effective in protecting the dopamine [nerves] from dying, and also
stimulates some regeneration. There are some unknowns, some things to
work out before it goes to the clinic, but I think that a clinical trial
is not too far away in this area," says Bohn, who was not involved in
the study.
The therapy could be studies in humans within five years, agrees lead
author Jeffrey H. Kordower, PhD. He is professor of neurological
sciences and director of the Research Center for Brain Repair at
Rush-Presbyterian-St. Luke's Medical Center.
And Parkinson's disease may be just the beginning, according to the
author of an editorial accompanying the study. "Cocktails" of genes for
various nerve growth factors could be delivered safely with these
viruses to the desired areas of the brain and spinal cord to treat not
just Parkinson's disease but also "an entire spectrum of other central
nervous disorders," writes Lars Olson, PhD, professor of neurobiology at
the Karolinska Institute in Stockholm, Sweden.
The researchers performed brain scans and other tests on the monkeys
before and three months after the treatment. The growth factor appeared
to not only halt the destruction of dopamine-producing nerves but also
allowed dopamine production to return to near-normal levels.
Kordower and colleagues also showed that the treatment caused the growth
factor to stay at high levels for at least eight months, and quite
possibly longer. "We have over one-year data in rats, and there's no
evidence in any study that we've done where we've ever looked and not
seen it," Kordower tells WebMD.
Bohn explains that patients usually don't have symptoms of the disease
until the majority of their dopamine-producing nerves are lost. So "if
you can [increase the dopamine output] of the [nerves] that are left, I
say that you cure the disease -- you don't replace the [nerves] they've
lost, but you get rid of the symptoms."
? 2000 WebMD Corporation. All rights reserved.
Envoi de pieces-jointes : piece-jointe@parkliste.org
Site Parkliste : http://www.parkliste.org
Liste Partenaires (conjoints et proches)envoyer un message vide ŕ :join-Partenaires@lyris.coles.org.uk
Sent to: [marciliosantos@hotmail.com]
Nenhum comentário:
Postar um comentário
Observamos que muitos comentários são postados e não exibidos. Certifique-se que seu comentário foi postado com a alteração da expressão "Nenhum comentário" no rodapé. Antes de reenviar faça um refresh. Se ainda não postado (alterado o n.o), use o quadro MENSAGENS da coluna da direita. Grato.